Hydrodynamic Cavitation in Pharmaceutical Particle Engineering, Crystallization, and Drug Delivery

7 Particle Design, Encapsulation, and Surface Stabilization

7.1 Surface Creation Must Be Coupled with Stabilization

Every reduction in particle or droplet size creates new interface. The formulation must stabilize that interface on the same time scale as it is created. Electrostatic stabilization uses surface charge and the resulting repulsive interaction. Steric stabilization uses adsorbed polymers or surfactants that create an excluded volume barrier. Electrosteric systems combine both. Lipid coating can alter wetting, protect a drug surface, reduce direct contact with tissue, or provide a controlled release barrier. The correct mechanism depends on the continuous phase, ionic strength, route of administration, excipient acceptability, and intended downstream operation [1,7,15,16].

Stabilizer underdosing leaves unprotected surface and promotes aggregation. Excess stabilizer can create micelles, change osmolality, alter drug partitioning, increase free excipient, or complicate purification. A rational approach estimates newly created surface area, measures adsorption where possible, and uses a design of experiments to evaluate particle size, free stabilizer, viscosity, zeta potential, dissolution, and storage stability together.

7.2 Lipid Coated Particles, Polymer Nanoparticles, and Hybrid Carriers

The Microfluidics nanoencapsulation materials describe three broad carrier platforms: nanoemulsions, liposomes, and polymer particles. The bottom up MRT examples include polycaprolactone and poly(lactide co glycolide) particles formed by solvent and antisolvent precipitation. The supplied materials report a polycaprolactone median size of 239 nm and a poly(lactide co glycolide) example with average sizes of 141 nm by solvent and antisolvent precipitation and 108 nm by nanoemulsion evaporation [18]. These data illustrate how polymer precipitation and emulsion evaporation can be integrated with intensive micromixing.

Hybrid structures can combine a crystalline or amorphous drug core with a lipid or polymer shell. Such systems may improve wetting and retention while preserving high drug loading. However, morphology must be demonstrated. A small DLS diameter alone cannot distinguish a solid core lipid shell particle from a liposome, micelle, nanoemulsion, or polymer aggregate. Orthogonal imaging and compositional separation are necessary.

7.3 Coating and Encapsulation Performance Measures

A development report should separate three questions. First, how much drug is associated with the carrier fraction? Second, where is the drug located within the structure? Third, how stable is that association during processing, storage, dilution, and administration? Encapsulation efficiency addresses the first question, while microscopy, spectroscopy, partition measurements, and release studies address the second and third. For a lipid coated crystal, drug loading can be high because the drug is the core. For a conventional liposome, loading is constrained by aqueous volume, bilayer capacity, remote loading gradients, and the drug to lipid ratio.

Surface treatment performed in the active processing zone can be advantageous because stabilizer encounters newly created surface before substantial reagglomeration. The process can be staged by using an upstream module for deagglomeration, a high energy zone for size reduction, and a lower energy downstream stage for coating or equilibration. The optimum order depends on adsorption kinetics and whether the stabilizer itself is shear sensitive.

7.4 Storage Stability and Redispersion

The final particle size at the processor outlet is only an initial condition. Stability studies should evaluate sedimentation, creaming, aggregation, crystal growth, polymorphic conversion, leakage, oxidation, hydrolysis, and container interaction. Accelerated stress can be useful, but the stress mechanism must remain relevant to normal storage. Freeze thaw studies are important when frozen storage is possible. Lyophilized systems require evaluation of cake structure, residual moisture, reconstitution time, and post reconstitution particle distribution.

A redispersible sediment can be acceptable for some oral or topical suspensions but may be unacceptable for parenteral or ophthalmic use. Redispersion testing should be quantitative where possible, using a defined inversion, shaking, or mixing protocol followed by dose uniformity and particle size testing. For a continuous process, hold time and agitation in intermediate vessels should be included in the stability design.